News | October 15, 2021
Expect normal quarter in Q2FY22: Emkay
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
_256_384.jpg)
It works by collecting aerosols and identifies the presence of dangerous pathogens using sensitive, specific and rapid detection in near-real time without laboratory analysis
The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
It has planned an investment of over Rs 80 crore in the next five years
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
HCL will establish a joint centre of excellence (CoE) for Google Cloud with industry subject matter experts and Google Cloud-certified ideapreneurs
Since its inception, the company has either acquired or taken a majority stake in five companies
Subscribe To Our Newsletter & Stay Updated
